Skip to content
value.today
Curis, Inc. logo

Curis, Inc.

CRIS
$5 Mmarket cap on Oct 30, 2026-93.8% since Jan 2024
Compare
World rank
#26,837
Revenue
$9 M
For year ending December-2025
Net income
$-8 M
-80.3% margin
SEC filing
Employees
—

Curis, Inc. in brief

Curis, Inc. is a listed company in the Biotechnology industry, based in Lexington, Massachusetts, USA. Its market value was $5 M on 30 October 2026, which makes it the 26,837th largest listed company in the world and the 4,398th largest in the USA on this site. In the year to December 2025 it had sales of $9 M and a net loss of $8 M. James E. Dentzer is its chief executive. Its shares trade under the symbol CRIS (Nasdaq).

Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.

About Curis, Inc.

Curis working to develop innovative and differentiated therapeutics that improve the lives of cancer patients. Headquarters is in USA.

Curis, Inc. timeline

2 events, 2000–2024
  1. 2000
  2. •
    · approximate
    First filing with the US SEC
    The company's first electronic filing in SEC EDGAR.
  3. 2024
  4. 💰
    Record revenue of $11 million
    FY2024, the highest of the 8 years on record.

Events of Curis, Inc. from SEC EDGAR and the company's financial years. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.

Market cap history

$0 M$185 M$370 M$556 M$741 M2020202120222023202420252026

World rank over time

▼ down 5,908 places since 2020
2020-01-01: #20938#20,93820202021-01-01: #9638#9,63820212022-01-07: #16211#16,21120222022-12-25: #25474#25,47420222023-07-30: #23010#23,01020232024-01-05: #22271#22,27120242026-03-08: #12466#12,46620262026-08-01: #23751#23,75120262026-10-14: #26762#26,76220262026-10-30: #26846#26,8462026

Rank in USA: #3,999 (Jan 2020) · #2,496 (Jan 2021) · #3,393 (Jan 2022) · #4,814 (Dec 2022) · #4,425 (Jul 2023) · #3,805 (Jan 2024) · #2,345 (Mar 2026) · #4,143 (Aug 2026) · #4,336 (Oct 2026) · #4,399 (Oct 2026)

Key ratios

market cap and latest results
P/E ratio
n/m (loss)
Price / sales
0.6×
Price / book
1.0×
Free cash flow yield
-734.8%
Net margin
-80.3%
Operating margin
-60.5%
Return on equity
-138.8%
Liabilities / assets
72.6%
Net debt
$-129M
Revenue growth
-13.5%
R&D / revenue
299.3%

Financial history

USD · fiscal years · source: SEC filings
RevenueNet income
Fiscal year ending Dec 2018: revenue $10M, net income $-33M$10MFY18Fiscal year ending Dec 2019: revenue $10M, net income $-32M$10MFY19Fiscal year ending Dec 2020: revenue $11M, net income $-30M$11MFY20Fiscal year ending Dec 2021: revenue $11M, net income $-45M$11MFY21Fiscal year ending Dec 2022: revenue $10M, net income $-57M$10MFY22Fiscal year ending Dec 2023: revenue $10M, net income $-47M$10MFY23Fiscal year ending Dec 2024: revenue $11M, net income $-43M$11MFY24Fiscal year ending Dec 2025: revenue $9M, net income $-8M$9MFY25
Fiscal year endingRevenueGrowthOperating incomeNet incomeNet margin
Dec 2025$9M-13.5%$-6M$-8M-80.3%
Dec 2024$11M+8.9%$-45M$-43M-397.7%
Dec 2023$10M-1.4%$-48M$-47M-473.2%
Dec 2022$10M-4.6%$-53M$-57M-557.8%
Dec 2021$11M-1.8%$-42M$-45M-426.7%
Dec 2020$11M+8.4%$-25M$-30M-275.9%
Dec 2019$10M-4.1%$-24M$-32M-321.4%
Dec 2018$10M—$-29M$-33M-312.4%

Cash flow, debt and per share

Fiscal year endingOperating cash flowCapital spendingFree cash flowEPS (diluted)Dividend / share
Dec 2025$-27M——$-0.58—
Dec 2024$-40M——$-6.88—
Dec 2023$-38M$0M$-38M$-8.96—
Dec 2022$-54M$0M$-55M$-12.14—
Dec 2021$-38M$0M$-38M$0.50—
Dec 2020$-26M$1M$-26M$-0.61—
Dec 2019$-26M$0M$-26M$-0.97—
Dec 2018$-30M$0M$-30M$-0.98—

Quarterly results

USD · three months to · source: SEC filings
RevenueNet income
Three months to Dec 2024 (from the annual report): revenue $3M, net income $-10M$3MDec ’24Three months to Mar 2025: revenue $2M, net income $-11M$2MMar ’25Three months to Jun 2025: revenue $3M, net income $-9M$3MJun ’25Three months to Sep 2025: revenue $3M, net income $-8M$3MSep ’25Three months to Dec 2025 (from the annual report): revenue $1M, net income $19M$1MDec ’25Three months to Mar 2026: revenue —, net income $-24M—Mar ’26Three months to Jun 2026: revenue —, net income $-9M—Jun ’26Three months to Sep 2026: revenue —, net income $-8M—Sep ’26

Latest quarter to Sep 2026: revenue —, net income $-8M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Jun 2026.

SEC filings

Official filings of Curis, Inc. with the US Securities and Exchange Commission.

Annual results

Revenue
$9 M
Operating income
$-6 M
Net income
$-8 M

For year ending December-2025 · source: SEC filing

Balance sheet

Total assets
$20 M
Total liabilities
$15 M
Total equity
$5 M

As of December-2025

Top 28 institutional investors in Curis, Inc.#

As of Sep 30, 2026
28 institutions held 1.2 M shares (about 55.4% of the shares outstanding) on Sep 30, 2026. The ten largest hold 50.9%. Source: SEC Form 13F filings, filed through Nov 17, 2026. Change is since the previous quarter.This quarter is still being filed: about 99% of the institutions that reported last quarter have filed so far. Institutions that have not filed yet are missing from the list, not sellers; the list is brought up to date every day.
The 25 largest institutional investors in Curis, Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
1Armistice Capital, LLC372,000New17.80%$0 MNov 16, 2026
2Bleichroeder LP190,116New9.10%$0 MNov 13, 2026
3Dauntless Investment Group, LLC100,004New4.78%$0 MNov 16, 2026
4Nantahala Capital Management, LLC93,824New4.49%$0 MNov 13, 2026
5Morgan Stanley87,336New4.18%$0 MNov 13, 2026
6Cable Car Capital, LP66,667New3.19%$0 MNov 16, 2026
7Two Sigma Investments, LP43,931New2.10%$0 MNov 16, 2026
8HRT Financial LP41,445New1.98%$0 MNov 13, 2026
9Sphera Funds Management LTD.39,665New1.90%$0 MNov 16, 2026
10Vanguard Capital Management LLC29,190New1.40%$0 MNov 13, 2026
11Virtu Financial LLC19,771New0.95%$0 MNov 17, 2026
12Geode Capital Management, LLC18,745New0.90%$0 MNov 6, 2026
13Citadel Advisors LLC16,682New0.80%$0 MNov 16, 2026
14M28 Capital Management LP14,244New0.68%$0 MNov 13, 2026
15FNY Investment Advisers, LLC7,685New0.37%$0 MOct 16, 2026
16Tower Research Capital LLC (TRC)7,099New0.34%$0 MNov 16, 2026
17UBS Group AG3,391New0.16%$0 MNov 10, 2026
18Vanguard Fiduciary Trust Co3,083New0.15%$0 MNov 13, 2026
19BlackRock, Inc.1,990New0.10%$0 MNov 13, 2026
20Steward Partners Investment Advisory, LLC129New0.01%$0 MNov 13, 2026
21Jpmorgan Chase & Co89New0.00%$0 MNov 12, 2026
22Osaic Holdings, Inc.75New0.00%$0 MNov 12, 2026
23Wells Fargo & Company/mn71New0.00%$0 MNov 16, 2026
24BFC Planning, Inc.27New0.00%$0 MNov 13, 2026
25Group One Trading LLC22New0.00%$0 MNov 10, 2026
Show all 28: investors 26 to 28
Institutional investors 26 to 28 in Curis, Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
26Jones Financial Companies Lllp6New0.00%$0 MNov 13, 2026
27SBI Securities Co., Ltd.6-9 (-60.00%)0.00%$0 MOct 22, 2026
28Caitong International Asset Management Co., Ltd3New0.00%$0 MOct 29, 2026

Mutual funds holding Curis, Inc.#

6 funds hold shares worth $0 M. Since their previous reports 2 added shares and 1 sold.
Mutual funds holding Curis, Inc.
FundSharesValueOf the companyOf the fundChange in sharesReport
🇺🇸 Vanguard Total Stock Market Index FundThe Vanguard Group, Inc.215,599$0 M—<0.01%no changeJun 30, 2026
🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC116,491$0 M—<0.01%+111%May 31, 2026
🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc.96,043$0 M—<0.01%no changeJun 30, 2026
🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC17,693$0 M—<0.01%+34%May 31, 2026
🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC10,208$0 M—<0.01%no changeMay 31, 2026
🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC2,839$0 M—<0.01%no changeMay 31, 2026

Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jun 30, 2026. The 6 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.

Insider trading at Curis, Inc.#

Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.

Bought, 12 months
$6 K
1 purchase, 1 insider
Sold, 12 months
$0
0 sales, 0 insiders
Net, 12 months
$6 K
open market only
Insiders on file
19
since
Curis, Inc.: latest insider trades
TradedInsiderTradeSharesPriceValueOwned afterFiling
filed Kenneth I. KaitinDirectorBuy+10,000$0.550$6 K11,407Form 4
filed James E. DentzerPresident & CEO, DirectorConversion+133,333——148,730Form 4
filed Marc RubinDirectorConversion+26,667——28,108Form 4
filed Diantha DuvallCFOConversion+66,666——77,707Form 4
filed Ahmed HamdyCMOConversion+66,667——66,667Form 4
filed Jonathan B. ZungCDOConversion+66,667——66,667Form 4
filed James E. DentzerPresident & CEO, DirectorSell10b5-1 plan-3,094$3.070$9 K64,877Form 4
filed James E. DentzerPresident & CEO, DirectorSell-2,406$3.180$8 K67,971Form 4

Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals

Markets and events: Curis, Inc.#

Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.

Short interest, 2026-10-30
1.0 M
1.12 days to cover
Reg SHO threshold list
13 days
in the last 90 days
Shares sold short, last 24 reportsAll stocks →

Stock splits: 1-for-20 reverse split ; 1-for-20 reverse split ; 1-for-5 reverse split

Trading halts

  • 2026-11-04 14:50 UTC, code LUDP, resumed 14:55 UTC
  • 2026-11-04 14:45 UTC, code LUDP, resumed 14:50 UTC
  • 2026-11-04 14:34 UTC, code LUDP, resumed 14:39 UTC
  • 2026-11-03 17:56 UTC, code LUDP, resumed 18:01 UTC
  • 2026-11-03 17:49 UTC, code LUDP, resumed 17:54 UTC

Fails to deliver

  • : 272,839 shares at $0.55
  • : 175,064 shares at $0.45
  • : 181,345 shares at $0.40
  • : 116,920 shares at $0.38
  • : 3,112 shares at $0.39

Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables

Curis, Inc. scorecard#

Passes 4 of the 18 checks that could be worked out: strongest in valuation (2 of 4), weakest in financial health (0 of 3). Fiscal year 2025; market cap of Oct 30, 2026.

  • Valuation2 of 4
    • ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
    • ✓Price to book below its peers' median1.0×Price to book 1.0× against Biotechnology's median of 2.9×.
    • ✓Price to sales below its peers' median0.6×Price to sales 0.6× against Biotechnology's median of 8.7×.
    • –Free cash flow yield above 5%No free cash flow yield on file.
    • ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
    • –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
  • Growth1 of 6
    • ✗Revenue grew in the newest year-13.5%Revenue down 13.5% in fiscal 2025.
    • ✗Revenue up more than 5% a year over three years-2.4%-2.4% a year over the three years to fiscal 2025.
    • ✗Faster growth over three years than its peers' median-2.4%-2.4% a year against Biotechnology's median of 12.9% (181 companies).
    • ✗Earnings per share grew in the newest year-0.58 vs -6.88Diluted EPS -0.58 in fiscal 2025 against -6.88 the year before (report's currency).
    • ✓Net income higher than five years earlier-$8 M-$8 M in fiscal 2025 against -$30 M in 2020.
    • ✗Revenue rose in at least four of the last five years1 of 5Revenue rose in 1 of the five years to fiscal 2025.
  • Profitability1 of 4
    • ✗Profitable in the newest year-$8 MNet income -$8 M in fiscal 2025.
    • ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
    • ✗Operating margin above its peers' median-60.5%-60.5% against Biotechnology's median of -60.5% (243 companies).
    • –Return on equity above 15%No return on equity (equity missing or negative).
    • –Return on invested capital above 10%No return on invested capital on file.
    • ✓Operating margin wider than three years earlier-60.5%-60.5% in fiscal 2025 against -521.9% in 2022.
  • Financial health0 of 3
    • ✗Short-term assets cover short-term liabilities0.5×Current ratio 0.49 at the end of fiscal 2025.
    • –Debt below equityDebt or equity is not on file (or equity is negative).
    • –Net debt below three years of EBITDANet debt to EBITDA is not on file.
    • –Operating income covers interest five timesInterest expense is not on file.
    • ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
    • ✗Altman Z-score outside the distress zone-88.13Z-score -88.13 (distress zone) for fiscal 2025.
  • Shareholder returns0 of 1
    • –Pays a dividendDividends are not on file.
    • –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
    • –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
    • ✗Share count up no more than 2% in a year108.8%Diluted shares up 108.8% in fiscal 2025.
    • –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
    • –Free cash flow covers dividends and buybacksCash from operations or capital spending is not on file.

Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work

Financial analysis, 2025#

Worked out from Curis, Inc.'s statements, beside the median of Biotechnology.

Curis, Inc.: main financial ratios in 2025
Ratio2025Median of peers
Operating margin-60.5%-60.5%
Net margin-80.3%-68.9%
Revenue growth, 3 years a year-2.4%12.9%
Revenue growth-13.5%15.8%

3of 7on the Piotroski tests of financial strength

  • Revenue fell 13.5% against the year before.
  • Net loss of $8 million, the 17th loss-making year in a row.
  • The share count rose 108.8% in the year.
  • Liabilities due within a year exceed current assets (current ratio 0.49).

Curis, Inc.: financial statements#

Income statement, balance sheet and cash-flow statement as reported, newest period first.

Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).

Curis, Inc.: statements by fiscal year
PeriodTrendFY 2025to Dec 31, 2025FY 2024to Dec 31, 2024FY 2023to Dec 31, 2023FY 2022to Dec 31, 2022FY 2021to Dec 31, 2021FY 2020to Dec 31, 2020FY 2019to Dec 31, 2019FY 2018to Dec 31, 2018FY 2017to Dec 31, 2017FY 2016to Dec 31, 2016
Income statement
Revenue9.4111010111110109.97.5
Research and development28393943352322244518r
General and administrative14171920171212151416
Total costs and expenses42555863533634406066
Operating income−5.7−45−48−53−42−25−24−29−50−58
Interest and finance income0.31.82.91.10.20.10.60.70.50.4
Interest expense and finance costs————000.83.94.02.8
Other non-operating income (expense)−1.91.20.9−3.7−3.4−5.0−7.8−3.2−3.6−2.4
Income tax00————————
Net income attributable to shareholders−7.6−43−47−57−45−30−32−33−53−60
Earnings per share, basic-0.58-6.88-8.96-12.14r0.50r-0.61-0.97-0.98-1.79r-0.45
Earnings per share, diluted-0.58-6.88-8.96-12.14r0.50r-0.61-0.97-0.98-1.79r-0.45
Shares, weighted average (basic)136.35.34.7r924933———
Shares, weighted average (diluted)136.35.34.7r9249333330r133
Balance sheet
Cash and cash equivalents5.12027204013015243826
Short-term investments—0306676395.1r0.62218
Receivables03.32.83.03.23.03.22.93.12.5
Other current assets1.93.01.83.53.31.21.10.81.01.3
Current assets6.926619212217325286448
Property, plant and equipment0.10.20.40.70.50.70.20.30.40.4
Right-of-use (leased) assets1.93.23.14.45.76.60.1———
Goodwill9.09.09.09.09.09.09.09.09.09.0
Long-term investments———024150———
Total assets20417710916220435377458
Accounts payable5.63.03.23.26.44.24.52.95.45.9
Debt due within a year07.68.5—00.606.9r5.9r4.9
Current liabilities141922r1013106.5131414
Long-term debt—————0.30293615
Lease liabilities (non-current)0.41.61.52.84.45.00———
Total liabilities15475862727469425028
Retained earnings−1,247−1,240−1,196−1,149−1,092−1,047−1,017−985−952−899
Shareholders' equity5.5−6.0204791131−34−4.52429r
Total liabilities and equity20417710916220435377458
Shares outstanding0.6r8.55.94.8r9292333333r141
Cash-flow statement
Depreciation and amortization0.20.20.30.20.20.10.10.20.20.2
Share-based compensation4.05.96.06.85.32.72.73.95.44.3
Cash from operating activities−27−40−38−54−38−26−26−30−48−36
Capital expenditure——0−0.40−0.7−0.0−0.1−0.2−0.3
Cash from investing activities2.5293833−48−49−4.521−3.630
Debt issued————00.90———
Debt repaid————00−1.8−6.1−5.0−4.3
Shares issued1512145.8r015900420
Cash from financing activities9.83.47.60.9−4.218923−6.064−1.4
Change in cash−15−6.76.9−20−90114−7.4−1512−7.1
Report10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K

r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies

Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.

Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative

Events at Curis, Inc.#

What the company reported to the SEC within four business days (Form 8-K), newest first.

Warning signs in the last three years

  • Delisting noticeFiling
  • Delisting noticeFiling
  • Delisting noticeFiling
  • Delisting noticeFiling
  • Delisting noticeFiling
  • Delisting noticeFiling

Delisting notice 6 · Acquisition or sale completed 1 · Directors and officers 2 · Material agreement 4 · Agreement ended 1 · Unregistered share sale 4 · Shareholder rights changed 4 · Bylaws or fiscal year changed 7 · Shareholder vote 4 · Results announced 7

Curis, Inc.: events reported to the SEC
FiledWhat happenedFiling
Delisting notice8-K
Material agreementUnregistered share sale8-K
Delisting notice8-K
Shareholder rights changedBylaws or fiscal year changed8-K
Bylaws or fiscal year changed8-K
Bylaws or fiscal year changed8-K/A
Shareholder vote8-K
Shareholder rights changedBylaws or fiscal year changedShareholder vote8-K
Results announced8-K
Delisting notice8-K
Results announced8-K
Directors and officersShareholder rights changedBylaws or fiscal year changedShareholder vote8-K
Delisting notice8-K
Material agreementUnregistered share saleBylaws or fiscal year changed8-K
Acquisition or sale completedAgreement endedResults announced8-K
Delisting notice8-K
Delisting notice8-K
Results announced8-K
Material agreementUnregistered share sale8-K
Directors and officersShareholder rights changedBylaws or fiscal year changedShareholder vote8-K
Results announced8-K
Results announced8-K
Material agreementUnregistered share saleResults announced8-K

Source: SEC EDGAR, Form 8-K item numbers · as of Nov 6, 2026

H-1B hiring at Curis, Inc.#

1 labor condition applications certified in fiscal 2026 for 1 positions, at a median wage of $205 K a year.

Certified, FY2026
1
#1,890 among companies on value.today
Worker positions
1
Median wage offered
$205 K
a year, full-time
Applications filed
1
Curis, Inc.: most frequent H-1B job titles in fiscal 2026
Job titlePositionsMedian wage offered
Associate Director, Clinical SciencesMedical Scientists, Except Epidemiologists1$205 K

Where: Lexington, MA 1

Curis, Inc.: labor condition applications by fiscal year
Fiscal yearCertifiedPositionsMedian wageFiled
FY202611$205 K1
FY202422$234 K2
FY202222$175 K2
FY202111$225 K1

Source: US Department of Labor, LCA disclosure data. An application is not a visa: USCIS decides each petition later, and the yearly lottery limits new H-1B visas. Filed as Curis, Inc.

How Curis, Inc. compares in Biotechnology

  • Market cap$5 M · higher than 6% of 726
  • Revenue$9 M · higher than 42% of 647
  • Net margin-80.3% · higher than 44% of 408
  • Revenue growth-13.5% · higher than 32% of 438
  • Price / sales0.6× · lower than 97% of 339
  • Price / book1.0× · lower than 80% of 534

Peer comparison · Biotechnology

CompanyMarket capP/ENet marginRev. growth
Curis, Inc.🇺🇸$5 M—-80.3%-13.5%
Novo Nordisk A/S🇩🇰$203.2 B13.1×33.1%+10.8%
Vertex Pharmaceuticals Incorporated🇺🇸$134.3 B33.8×30.7%+8.9%
Moderna, Inc.🇺🇸$90.1 B—-110.5%-39.9%
Regeneron Pharmaceuticals, Inc.🇺🇸$84.1 B17.5×28.5%+1.0%
Argenx SE🇳🇱$52.8 B40.9×31.1%+89.9%
CSL Limited🇦🇺$51.6 B—-16.4%—
Samsung Biologics Co., Ltd.🇰🇷$51.5 B40.5×39.2%—
UCB SA🇧🇪$48.6 B26.3×20.1%+31.1%

P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.

Questions, comparisons and similar companies#

Sources and freshness

Market cap:
Oct 30, 2026
Annual results:
For year ending December-2025
Balance sheet:
As of December-2025
Profile updated:
Nov 20, 2026

Figures from Market data, SEC filing, value.today research, GLEIF register; financial statements from SEC filings.

How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.

Work at Curis, Inc.? Verify and update this profile — free

Use your work e-mail address (on the company's own domain if possible). Fill in only what is new or missing; a link to where the figures are published (annual report, press release) speeds up the review.

Show Curis, Inc.'s ranking or a chart on your website Get the badge
Badge preview

The badge updates itself as the ranking changes.

Something wrong or missing about Curis, Inc.? Suggest a correction